7R8 Stock Overview
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Replimune Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.75 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$5.75 |
| Beta | 1.2 |
| 1 Month Change | -19.58% |
| 3 Month Change | -20.14% |
| 1 Year Change | -61.67% |
| 3 Year Change | -80.70% |
| 5 Year Change | -58.01% |
| Change since IPO | -52.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7R8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.2% | -0.2% | 0.5% |
| 1Y | -61.7% | -22.8% | 1.3% |
Return vs Industry: 7R8 underperformed the German Biotechs industry which returned -22.8% over the past year.
Return vs Market: 7R8 underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 7R8 volatility | |
|---|---|
| 7R8 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7R8's share price has been volatile over the past 3 months.
Volatility Over Time: 7R8's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 284 | Sush Patel | www.replimune.com |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Replimune Group, Inc. Fundamentals Summary
| 7R8 fundamental statistics | |
|---|---|
| Market cap | €351.79m |
| Earnings (TTM) | -€195.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs 7R8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7R8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$209.96m |
| Earnings | -US$209.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 10.5% |
How did 7R8 perform over the long term?
See historical performance and comparison